Project Grant R01HL176839
Award Date
5/1/25
Completion Date
2/28/30
Dollars Obligated
$772K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This five-year, $1,644,550 Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a comprehensive research project to study the cell-cell and cell-matrix interactions that drive progressive fibrosis in interstitial lung diseases (ILDs). The key objectives are to: 1) Understand epithelial-mesenchymal interactions in the airway that drive fibrosis using spatial transcriptomics; 2)...
This Project Grant award of $196,245 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research by Dr. Pugashetti at the University of Michigan to develop predictive biomarkers for treatment failure in patients with connective tissue disease-associated interstitial lung disease (CTD-ILD). The key objectives are to: 1) Determine the trajectory of lung function decline and incidence of treatment failure across...
The $837,883 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) will support research to develop a novel prognostic approach for predicting progression of interstitial lung abnormalities (ILA) to progressive pulmonary fibrosis (PPF). The primary awardee, the General Hospital Corporation (dba Massachusetts General Hospital), will utilize endobronchial optical coherence tomography (EB-OCT) to detect...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $539,218 to The Trustees of the University of Pennsylvania to develop and validate novel risk prediction models and identify subphenotypes of myositis-associated interstitial lung disease (ILD). The goal is to generate tools to better prognosticate clinical outcomes and guide precision therapy for this highly morbid complication of...
This $774,585.00 federal Project Grant award from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports comprehensive research to investigate the mechanisms underlying the emergence and functional role of inflammatory fibroblasts in pulmonary fibrosis. The key objectives of the research project are to: 1) compare the timing, persistence, and fate of inflammatory fibroblasts in models of pulmonary fibrosis versus inflammation...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $604,115.00 to The General Hospital Corporation (doing business as Massachusetts General Hospital) for a longitudinal observational study. The study aims to determine if advanced PET and MRI imaging technologies can predict which individuals with non-IPF interstitial lung disease (ILD) will develop progressive pulmonary fibrosis...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), totals $542,402 and will be conducted from April 1, 2025 to March 31, 2026. The grant aims to identify small molecules that can reverse profibrotic gene signatures in idiopathic pulmonary fibrosis (IPF), a debilitating lung disease with no effective treatments. The researchers will use large-scale single-cell RNA sequencing and artificial...
This federal Project Grant award, valued at $787,266.00 and provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), is targeting the Wnt7a signaling pathway in idiopathic pulmonary fibrosis (IPF). The research aims to investigate the role of basal-like cells in IPF and their contribution to excessive Wnt7a production, which can promote fibroblast activation and impair the renewal of alveolar epithelial stem cells. The...
This $100,000 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) supports research to understand the role of immune and inflammatory cells in driving lung fibrosis associated with systemic sclerosis (SSc), a complex autoimmune disease. The researchers will use a novel explant culture model of SSc-associated interstitial lung disease (SSc-ILD) to examine the effects of key cytokines implicated in...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $162,540 to The Trustees of the University of Pennsylvania for a 2-year research project starting on September 1, 2024. The project aims to investigate the impact of aging on mitochondrial quality control, metabolic disruption, and alveolar epithelial type 2 (AT2) progenitor cell function in pulmonary fibrosis. The research...